ASH 2020 | Advances in ALL in the UK: UKALL14 and ALL-RIC
David Marks
• 4 Dec 2020
David Marks, MB, MS, FRACP, PhD, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses advances in acute lymphocytic leukemia (ALL) in the UK. The results of the UKALL14 trial (NCT01085617) of rituximab added to standard induction chemotherapy will soon be published, as well as encouraging results from a reduced-intensity transplant study. Prof. Marks also discusses the ongoing ALL-RIC project, which compares conditioning regimens for reduced intensity transplant with the aim to reduce relapse and prolong survival, as well as CAR-T data for ALL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
